Sign In
Buy QURE
$46.06
-0.360 (-0.776%)
At Close: Aug 10, 2026
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
12:01pm, Thursday, 30'th Jul 2026
uniQure posts a wider Q2 2026 loss as revenues missed estimates, but regulatory progress for AMT-130 and a cash runway into 2030 keep its pipeline in focus.
Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise, and a brutal semiconductor selloff forced some major rating reversals across insurance, gaming, te
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
02:53pm, Wednesday, 29'th Jul 2026
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
uniQure Q2 Earnings Call Highlights
01:05pm, Wednesday, 29'th Jul 2026
uniQure NASDAQ: QURE said it has aligned with the U.S. Food and Drug Administration on a potential accelerated-approval pathway for AMT-130, its investigational gene therapy for Huntington's disease,
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
09:31am, Wednesday, 29'th Jul 2026
uniQure (QURE) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.69 per share a year ago.
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
07:05am, Wednesday, 29'th Jul 2026
~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected i
uniQure to Announce Second Quarter 2026 Financial Results
07:05am, Wednesday, 22'nd Jul 2026
~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Wednesday, July 29, 2026 at 8:30 a.m. ET ~
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
03:56pm, Friday, 17'th Jul 2026
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
03:32pm, Friday, 17'th Jul 2026
QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
03:26pm, Friday, 17'th Jul 2026
QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?
10:55am, Wednesday, 01'st Jul 2026
uniQure N.V. (QURE) reached a significant support level, and could be a good pick for investors from a technical perspective.
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
04:10pm, Thursday, 25'th Jun 2026
LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
uniQure Announces Pricing of Upsized $225 Million Public Offering
09:13pm, Tuesday, 23'rd Jun 2026
LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
uniQure Announces $150 Million Proposed Public Offering
04:01pm, Monday, 22'nd Jun 2026
LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
11:31am, Monday, 22'nd Jun 2026
uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reductions and no serious safety events.
